# A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML)

> **NCT03125876** · PHASE1 · TERMINATED · sponsor: **Sunshine Lake Pharma Co., Ltd.** · enrollment: 12 (actual)

## Conditions studied

- Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** CT053PTSA

## Key facts

- **NCT ID:** NCT03125876
- **Lead sponsor:** Sunshine Lake Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-11-13
- **Primary completion:** 2019-08-19
- **Final completion:** 2019-08-19
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Company strategy adjustment
- **Last updated:** 2021-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03125876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03125876, "A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03125876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*